Targeting Breast Cancer Stem Cells
Targeting Breast Cancer Stem Cells
复制标题
DOI：
10.1200/jco.2009.27.5388
复制
发表时间：
2010-09-01
影响因子：
45.3
通讯作者：
Wicha, Max S.
中科院分区：
文献类型：
--
作者：
Liu, Suling;Wicha, Max S.
越来越多的证据表明，包括乳腺癌在内的许多癌症都含有显示干细胞特性的细胞群。这些乳腺癌干细胞由于其对放射和细胞毒性化疗的相对抗性，可能导致治疗抗性和复发。对调节这些细胞的途径的阐明导致了对潜在治疗靶点的鉴定。许多能够在临床前模型中靶向乳腺癌干细胞的药物目前正在进入临床试验。评估药物的疗效需要开发具有适当生物学和临床终点的创新临床试验设计。乳腺癌干细胞的有效靶向治疗有可能显着改善早期和晚期乳腺癌女性的预后。
There is increasing evidence that many cancers, including breast cancer, contain populations of cells that display stem-cell properties. These breast cancer stem cells, by virtue of their relative resistance to radiation and cytotoxic chemotherapy, may contribute to treatment resistance and relapse. The elucidation of pathways that regulate these cells has led to the identification of potential therapeutic targets. A number of agents capable of targeting breast cancer stem cells in preclinical models are currently entering clinical trials. Assessment of the efficacy of the agents will require development of innovative clinical trial designs with appropriate biologic and clinical end points. The effective targeting of breast cancer stem cells has the potential to significantly improve outcome for women with both early-stage and advanced breast cancer.